To determine the involvement of STAT3 signaling in the anti-tumor effects of diosmetin on osteosarcoma cells, we examined the proliferation ability of Saos-2 and U2OS cells by applying diosmetin (0.3 μM) with or without IL-6 (20 ng/mL). This evidence concerns the gene IL6 and osteosarcoma.